ArticleAnnals of the rheumatic diseases2023
The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease.
Article in Annals of the rheumatic diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Baricitinib in Calcium PyrophosphAte DePosiTion DIseaSe Trial - a Proof of Concept Phase II Clinical Trial
The Natural History Of Calcium Pyrophosphate Deposition And Gout: An Observational Clinical And Imaging Study - The Orienting Study
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Clinical features and diagnostic challenges in crowned dens syndrome: a systematic review and meta-analysis.Rheumatology international · 2025Pooled it
- Pooled it
- Efficacy and safety of 10 mg versus 30 mg of oral prednisolone for acute CPP crystal arthritis: findings of a randomized controlled trial.Clinical rheumatology · 2024Trial
- Diuretic-Induced Hypomagnesemia May Play a Key Role in the Development of Calcium Pyrophosphate Arthritis.Rheumatology and therapy · 2026Article
- Anti IL-6 Treatment for Calcium Pyrophosphate Disease Report of 4 Cases and a Short Literature Review.European journal of rheumatology · 2026Article
- Evaluation of crystal-related arthritis in patients with knee effusion: insights from ultrasonography, microscopy and radiography.Clinical rheumatology · 2026Article
- Article
- Crowned Dens Syndrome associated with rheumatoid arthritis: A case report of two patients with a systematic literature review.Caspian journal of internal medicine · 2026Article
- Crowned Dens Syndrome: A Case Report Describing Refractory Symptoms.Case reports in rheumatology · 2026Article
- Crystal deposition disease of the shoulder at uncommon sites: Diagnostic challenges and nomenclature issues in the absence of synovial fluid analysis.Rheumatology and immunology research · 2025Article
- Performance of ultrasonography in diagnosis of calcium pyrophosphate deposition disease amongst Bangladeshi patients: an observational study.Advances in rheumatology (London, England) · 2025Observational
- Ultrasonographic Assessment of Calcium Pyrophosphate Deposition Disease: A Comprehensive Review.Journal of personalized medicine · 2025Review
- Steroid or pseudogout? Analysis of white deposits in tissues during surgery.Archives of orthopaedic and trauma surgery · 2025Article
- Are There Definite Disease Subsets in Polymyalgia Rheumatica? Suggestions from a Narrative Review.Healthcare (Basel, Switzerland) · 2025Review
- Coronary artery calcium and atherosclerotic cardiovascular disease risk scores in patients with calcium pyrophosphate deposition disease.Rheumatology (Oxford, England) · 2025Article
- Cervical proprioception, postural control, and pain: unraveling the interconnected challenges in rheumatoid arthritis.Journal of orthopaedic surgery and research · 2025Article
- Editorial: Calcium pyrophosphate deposition disease.Frontiers in medicine · 2025Article
- Advanced imaging techniques in crystal arthritis.Therapeutic advances in musculoskeletal disease · 2025Review
- Lumbar Intraspinal Calcium Pyrophosphate Deposition: A Comprehensive Case Study.Journal of central nervous system disease · 2025Article
- Features Associated With Different Inflammatory Phenotypes of Calcium Pyrophosphate Deposition Disease: A Study Using Data From the International American College of Rheumatology/EULAR Calcium Pyrophosphate Deposition Classification Criteria Cohort.Arthritis & rheumatology (Hoboken, N.J.) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
57 authors at 20 institutions in 9 countries.
Funding
Abstract
objectiveCalcium pyrophosphate deposition (CPPD) disease is prevalent and has diverse presentations, but there are no validated classification criteria for this symptomatic arthritis. The American College of Rheumatology (ACR) and EULAR have developed the first-ever validated classification criteria for symptomatic CPPD disease.
methodsSupported by the ACR and EULAR, a multinational group of investigators followed established methodology to develop these disease classification criteria. The group generated lists of candidate items and refined their definitions, collected de-identified patient profiles, evaluated strengths of associations between candidate items and CPPD disease, developed a classification criteria framework, and used multi-criterion decision analysis to define criteria weights and a classification threshold score. The criteria were validated in an independent cohort.
resultsAmong patients with joint pain, swelling, or tenderness (entry criterion) whose symptoms are not fully explained by an alternative disease (exclusion criterion), the presence of crowned dens syndrome or calcium pyrophosphate crystals in synovial fluid are sufficient to classify a patient as having CPPD disease. In the absence of these findings, a score>56 points using weighted criteria, comprising clinical features, associated metabolic disorders, and results of laboratory and imaging investigations, can be used to classify as CPPD disease. These criteria had a sensitivity of 92.2% and specificity of 87.9% in the derivation cohort (190 CPPD cases, 148 mimickers), whereas sensitivity was 99.2% and specificity was 92.5% in the validation cohort (251 CPPD cases, 162 mimickers).
conclusionThe 2023 ACR/EULAR CPPD disease classification criteria have excellent performance characteristics and will facilitate research in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.